NCT03971162

Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age. Intravitreal injection of any anti-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more further injection for the recurrence or uncontrolled with 1+pro re nata (PRN) treatment within one year, and whether increasing the initial loading of intravitreal injection of anti-VEGF would be more efficacy for the controlling the PM-CNV remained unknown.

Conditions

• Myopic Choroidal Neovascularisation

Interventions

Type	Name	Description
DRUG	3+PRN	intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
DRUG	6+PRN	intravitreal injection of Conbercept 0.5mg every month repeated for 6 months

Timeline

• Start date: 2019-06-13
• Primary completion: 2022-12-01
• Completion: 2023-01-01
• First posted: 2019-06-03
• Last updated: 2023-03-30

Locations

1 site across 1 country: China